Treatment of Primary Aldosteronism When Disease Is Bilateral, Lateralization Is Unknown, or Surgery Is Not an Option
When primary aldosteronism cannot be addressed surgically — whether because the disease is bilateral, lateralization has not been established, or the patient declines or is not a candidate for surgery — long-term medical therapy becomes the central management strategy.
Clinical Scenario
Bilateral primary aldosteronism, lateralization status unknown, or lateralizing primary aldosteronism in an individual who declines surgery or is not a surgical candidate. In each of these situations, lifelong medical therapy is the standard approach.
Treatment Approach (Partial)
Therapy is built around a mineralocorticoid receptor antagonist (MRA), with spironolactone as the preferred agent given its availability and cost profile. An alternative MRA may be used in selected patients.
Agent selection criteria, initial dosing strategy, and the full clinical algorithm are available in the complete protocol.
Treatment Goals
The primary goal is blood pressure control. The secondary goal is achieving normal serum potassium. Potassium levels typically normalise within the first few days of MRA initiation.
References
DOI: 10.1210/clinem/dgaf284
- Lifelong medical therapy that includes an MRA is usually offered to individuals with bilateral PA or lateralization status unknown (refer to Question 6 for definition of lateralization) and to those who decline the surgical option or who are not surgical candidates.
- In individuals with primary aldosteronism (PA) receiving PA-specific medical therapy, we suggest spironolactone over other mineralocorticoid receptor antagonists (MRAs) due to its low cost and widespread availability.
- Clinicians may start at a relatively low dose MRA (spironolactone 12.5-25 mg/d or eplerenone 25 mg daily or twice daily).
- For individuals with more severe PA, especially if profound hypokalemia is present, a higher initial dose could be considered (spironolactone 50 mg/d or eplerenone 50 mg twice daily).
- The primary goal of therapy is control of BP.
- The secondary goal of therapy is achievement of normokalemia.
- Normalization of serum potassium usually occurs, even with lower-dose MRAs, in the first 3 to 5 days, so it is reasonable to reduce or discontinue any potassium supplements at day 2 to 4 of MRA initiation in all but the most severe hypokalemic cases.
View source ↗